ASPC: American Society for Preventive Cardiology

Study authors investigated the effect of physical activity as a modifiable risk factor among individuals living with high-risk hypertension in this subanalysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT).

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, explains how he works closely with patients and study sites in SURPASS-CVOT to avoid weight loss drug discontinuation and weight regain.

Post heart failure (HF)–related hospital discharge care was investigated among patients through evaluation of usage rates of the Heart Failure Health Storylines mobile health application.

Findings were presented by researchers from the UC Irvine Health School of Medicine at the 2023 American Society for Preventive Cardiology's Congress on CVD Prevention.

G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.

Outcomes for in-hospital mortality were compared between adult patients, women vs men, among those who had both acute myocardial infarction (AMI) and heart-related mechanical complications (MC).

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide.

With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, Melbourne, Australia. discusses contributions in the space from therapies with systemwide effects.

Emelia J. Benjamin, MD, ScM, Boston University Chobanian and Avedisian School of Medicine, is the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award. Here she describes what atrial fibrillation is, how the condition announces itself, and why this area of cardiovascular medicine is receiving so much attention.

The ASPC Congress on CVD Prevention is taking place in Arlington, Texas, July 21-23. Here, G.B. John Mancini, MD, University of British Columbia, emphasizes the importance of having an international perspective on preventive cardiology.

The ASPC 2023 Congress on CVD Prevention will take place in Arlington, Texas, from July 21-23, and in this interview, President-Elect Michael Shapiro, DO, FASPC, runs down what attendees should look most forward to this year.

Watch and see what Michael Shapiro, DO, FASPC, president-elect of the American Society for Preventive Cardiology, wants you to know about this year's ASPC Congress on CVD Prevention.

Katherine R. Tuttle, MD, FASN, FACP, FNKF, a nephrologist from the University of Washington and Providence Health Care, discussed new consensus guidelines that call for the early use of sodium glucose cotransporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, and finerenone in the care of patients with both chronic kidney disease (CKD) and diabetes.

New heart failure guidelines redefine stages of the disease to emphasize prevention, said Biykem Bozkurt, MD, PhD, but more must be done by payers to identify those at high risk.

Coverage from the 2022 Congress of the American Society for Preventive Cardiology (ASPC) in Louisville, Kentucky, featuring 3 experts on aspects of hypertension treatment: Keith C. Ferdinand, MD, of Tulane University School of Medicine; Kim Allan Williams, MD, of the University of Louisville; and George C. Bakris, MD, of the University of Chicago Medicine.

During the 2022 Congress of the American Society for Preventive Cardiology (ASPC), held in Louisville, Kentucky, Erin D. Michos, MD, MHS, of Johns Hopkins, and Pam R. Taub, MD, of UC San Diego Health, discussed how treatment of diabetes requires going beyond glucose-lowering therapies and including newer medications that offer cardiovascular benefits.

Martha Gulati, MD, MS, kicked off the symposium “Saving the Hearts of Women Through Prevention” ahead of the 2022 Congress of the American Society for Preventive Cardiology, which took place Friday through Sunday in Louisville, Kentucky.

Social determinants of health are major drivers of the inequities seen in health outcomes, and racism is clearly a social determinant tied to life expectancy, said Karol Watson, MD, PhD, in talk Sunday at the 2022 Congress of the American Society for Preventive Cardiology, held in Louisville, Kentucky.

Ty J. Gluckman, MD, FACC, FAHA, who is medical director of the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health in Portland, Oregon, addressed the 2022 Congress of the American Society for Preventive Cardiology meeting in Louisville, Kentucky.

Duke University’s Pamela S. Douglas, MD, spoke to cardiology professionals who gathered for the start of the 2022 Congress of the American Society for Preventive Cardiology (ASPC), in Louisville, Kentucky.